ReviewBritish journal of haematology2010
Activated protein C action in inflammation.
Review in British journal of haematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 82 citations in OpenAlex.
- Venous Thromboembolism and Gut Dysbiosis: Mechanistic Links Between Endotoxemia, Microbial Metabolites, and Thromboinflammation.Nutrients · 2026Review
- Regulation of histones in thromboinflammation.Frontiers in immunology · 2026Review
- Changes in gene regulation are associated with the evolution of resistance to a novel parasite.Frontiers in immunology · 2026Article
- DIA-based serum proteomics of the complement-coagulation cascade identifies candidate biomarkers for myasthenia gravis.Frontiers in neuroscience · 2026Article
- Mediating role of proteomics in the association between per- and polyfluoroalkyl substance exposure and blood pressure in youth.Environmental pollution (Barking, Essex : 1987) · 2025Article
- Review
- Loss of protein C vs protein S results in discrepant thrombotic phenotypes.Blood advances · 2025Article
- Mimicking immune complexes for efficient antibody responses.Frontiers in immunology · 2025Article
- The Multifaceted Roles of Thrombomodulin: Anti-coagulation, Anti-inflammation, and Anti-tumor Potential.Current pharmaceutical design · 2025Review
- Unraveling the Molecular Mechanisms of Activated Protein C (APC) in Mitigating Reperfusion Injury and Cardiac Ischemia: a Promising Avenue for Novel Therapeutic Interventions.Journal of cardiovascular translational research · 2024Review
- Natural Anticoagulant Protein Levels in Patients With Beta-Thalassemia Major: A Case-Control Study.Journal of hematology · 2024Article
- Article
- Platelet factor 4 improves survival in a murine model of antibiotic-susceptible and methicillin-resistantFrontiers in cellular and infection microbiology · 2023Article
- Coagulation Profile of COVID-19 Patients.Life (Basel, Switzerland) · 2022Review
- Elucidating mechanisms of genetic cross-disease associations at the PROCR vascular disease locus.Nature communications · 2022Article
- Targeting GαNature communications · 2021Article
- Bilateral Limbal Stem Cell Alterations in Patients With Unilateral Herpes Simplex Keratitis and Herpes Zoster Ophthalmicus as Shown by In Vivo Confocal Microscopy.Investigative ophthalmology & visual science · 2021Article
- Thrombomodulin facilitates peripheral nerve regeneration through regulating M1/M2 switching.Journal of neuroinflammation · 2020Article
- Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.Thrombosis and haemostasis · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Activated protein C (APC) is a natural anticoagulant that plays an important role in coagulation homeostasis by inactivating the procoagulation factor Va and VIIIa. In addition to its anticoagulation functions, APC also has cytoprotective effects such as anti-inflammatory, anti-apoptotic, and endothelial barrier protection. Recently, a recombinant form of human APC (rhAPC or drotrecogin alfa activated; known commercially as 'Xigris') was approved by the US Federal Drug Administration for treatment of severe sepsis associated with a high risk of mortality. Sepsis, also known as systemic inflammatory response syndrome (SIRS) resulting from infection, is a serious medical condition in critical care patients. In sepsis, hyperactive and dysregulated inflammatory responses lead to secretion of pro- and anti-inflammatory cytokines, activation and migration of leucocytes, activation of coagulation, inhibition of fibrinolysis, and increased apoptosis. Although initial hypotheses focused on antithrombotic and profibrinolytic functions of APC in sepsis, other agents with more potent anticoagulation functions were not effective in treating severe sepsis. Furthermore, APC therapy is also associated with the risk of severe bleeding in treated patients. Therefore, the cytoprotective effects, rather than the anticoagulant effect of APC are postulated to be responsible for the therapeutic benefit of APC in the treatment of severe sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.